University of North Carolina at Chapel Hill
Dr. Lund has made major contributions to defining the regulation of intestinal growth by insulin/insulin-like growth factor family of receptors and enterotrophic hormones. She was the first to clone the proglucagon gene and identify new intestinal hormones, glucagon-like peptide 1 (GLP1; under clinical trial in diabetes) and glucagon-like peptide 2 (GLP2; under trial as a trophic therapy in the GI tract). She has made major contributions to understanding how IGF/insulin and downstream signaling pathways regulate normal and aberrant growth of intestinal epithelium and their roles in intestinal cancer. Her current research focuses on dissecting the roles of IGF1R versus two insulin receptor isoforms (IR-A or IR-B) in obesity-associated tumorigenesis and in normal and tumor-derived intestinal stem cells. In other research, Dr. Lund defined suppressors of cytokine signaling (SOCS) as tumor suppressors and is currently exploring their roles in inflammatory bowel disease (IBD) associated colon cancer, stem cells and inflammation-induced fibrosis. Recent novel findings from the Lund Lab that high-fat diet: bacteria interactions promote intestinal inflammation during development of obesity. This led to recent collaborations to explore how nod-like receptors (NLRPs) and effector may impact diet-associated intestinal inflammation or the effect of obesity to promote precancerous adenomas or CRC. Other ongoing research addresses molecular and cellular mechanisms of fibrosis in inflammatory bowel disease and crosstalk between intestinal mesenchymal cells and intestinal epithelial stem cells during repair after injury.